Corey Casper, MD, MPH
As AAHI’s President and CEO, Dr. Casper oversees a scientific portfolio of vaccines, therapeutics, and diagnostics that provide comprehensive solutions to global health problems. He is also responsible for the overall operations at AAHI, executing AAHI’s strategy, assuring adequate resources to achieve AAHI’s important mission, and representing AAHI to local, national and international stakeholders.
Dr. Casper is a medical doctor with over 20 years of experience conducting translational and clinical research in cancer and infectious disease. He has authored more than 130 peer-reviewed scientific publications, served as the Principal Investigator for many large projects funded by the National Institutes of Health, the Department of Defense, the Doris Duke Charitable Foundation and others. His research has led to the licensure of immunotherapies, the advancement of vaccines through late stage clinical trials, the development and deployment of new diagnostic assays, and the detailed characterization of the molecular underpinnings of cancers and infectious diseases in Sub-Saharan Africa, and has contributed more than 125 peer-reviewed papers to the medical literature; he also serves as an inventor on several patents. Dr. Casper founded the first Global Oncology Program at a US designated comprehensive cancer center, and opened one of the first comprehensive cancer centers in sub-Saharan Africa – the Uganda Cancer Institute (UCI)/Hutchinson Center Cancer Alliance. This facility opened in 2015 and continues to serve as a leading center for cancer care, research, and medical education in East Africa.
In addition to his activities at AAHI, Dr. Casper remains a committed educator and is a Clinical Professor of Medicine and Global Health at the University of Washington, where he is also the Associate Director of the Centers for AIDS Research. He is an Affiliate Professor at the Fred Hutch Cancer Center, where he cares for patients with cancer and infectious diseases.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Recordati Rare DiseaseTopic:Castleman DiseaseDate added:03/25/2024Date updated:03/25/2024Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Stock OptionsIneligible company:Viracta TherapeuticsTopic:EBV Positive LymphomaDate added:03/25/2024Date updated:03/25/2024Relationship end date:01/01/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ImmunityBioTopic:RNA VaccinesDate added:03/25/2024Date updated:03/25/2024Relationship end date:03/02/2027
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Janssen PharmaceuticalTopic:VaccinesDate added:03/25/2024Date updated:03/25/2024Relationship end date:12/31/2024